LEADER 04569nam 2200625Ia 450 001 9910825074903321 005 20200520144314.0 010 $a1-61761-864-0 035 $a(CKB)2560000000067957 035 $a(EBL)3017851 035 $a(SSID)ssj0000411458 035 $a(PQKBManifestationID)12144844 035 $a(PQKBTitleCode)TC0000411458 035 $a(PQKBWorkID)10355071 035 $a(PQKB)10095879 035 $a(MiAaPQ)EBC3017851 035 $a(Au-PeEL)EBL3017851 035 $a(CaPaEBR)ebr10654822 035 $a(OCoLC)923653915 035 $a(EXLCZ)992560000000067957 100 $a20091215d2010 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAggressive breast cancer /$fRegina H. DeFrina, editor 205 $a1st ed. 210 $aNew York $cNova Science Publishers$dc2010 215 $a1 online resource (276 p.) 225 1 $aCancer etiology, diagnosis and treatments series 300 $aDescription based upon print version of record. 311 $a1-60876-881-3 320 $aIncludes bibliographical references and index. 327 $a""AGGRESSIVE BREAST CANCER ""; ""AGGRESSIVE BREAST CANCER ""; ""CONTENTS ""; ""PREFACE""; ""RESEARCH AND REVIEW ARTICLES""; ""THE HER2 ONCOGENE IN BREAST CANCER ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""HER PROTEIN RECEPTORS: SIGNAL TRANSDUCTION AND ONCOGENESIS ""; ""Intracellular Signaling Pathways ""; ""HER-Induced Cell Cycle Progression and Survival Pathways ""; ""OVER EXPRESSION OF HER2 AND THE PROGNOSIS OF INVASIVE BREAST CANCER ""; ""HER2 as A Prognostic Factor: Node-Positive Versus Node-Negative Disease""; ""HER Status and Lymphoid Infiltration "" 327 $a""HER2 and Progression of Early Breast Cancer Lesions to Invasive Carcinomas""""Relationship Between HER2 and Estrogen Receptor Expression ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""Evaluating HER2 in Breast Tissue ""; ""HER2 TARGETED THERAPY IN BREAST CANCER ""; ""The Role of Trastuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Pertuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Trastuzumab-DM1 in HER2 Overexpressing Breast Cancer "" 327 $a""Inhibiting Several HER Receptors: The Role of Lapatinib in HER2 Overexpressing Breast Cancer """"Circulating Serum HER2 Levels ""; ""PROPOSED RESISTANCE TO ANTI-HER2 THERAPIES ""; ""Altered Receptor-Antibody Interaction ""; ""Increased Signaling from other Receptors of the HER Family ""; ""Increased Signaling from other Receptors Activating the MAPK and PI3K Pathways ""; ""Constitutive Activation of Downstream Effectors ""; ""HER2 OVEREXPRESSION AND CHEMOTHERAPY ""; ""Anthracyclines ""; ""Taxanes ""; ""HER2 OVEREXPRESSION AND HORMONAL THERAPY "" 327 $a""CNS DISEASE IN HER2 OVEREXPRESSED BREAST CANCER """"CNS Metastases in Adjuvant Trials of Trastuzumab ""; ""Prognosis of CNS Metastases in HER2 Overexpressing Breast Cancer""; ""CONCLUSION ""; ""REFERENCES""; ""MULTI-DRUG RESISTANCE AS A PROBLEM CHALLENGING BREAST CANCER CHEMOTHERAPY ""; ""ABSTRACT ""; ""INTRODUCTION""; ""1) Non-Cellular MDR Mechanisms ""; ""2) Cellular MDR Mechanisms: ""; ""1. Changes in the intracellular accumulation and distribution of the drug ""; ""1a. Alteration of drug influx ""; ""1b. Alteration of drug efflux ""; ""NORMAL TISSUE DISTRIBUTION"" 327 $a""PHYSIOLOGICAL FUNCTIONS OF P-GP """"PHARMACOLOGICAL FUNCTIONS OF P-GP ""; ""P-GP SUBSTRATES ""; ""2. Increase in Drug Detoxification ""; ""3. Alterations of Drug Targets ""; ""4. Increase in DNA Repair Mechanism ""; ""5. Changes in Key Genes Controlling Cell Proliferation ""; ""5a. Changes in genes responsible for cell cycle control ""; ""5b. Abrogation of apoptosis ""; ""6. Micro-Environmental Stress-Mediated Resistance of Solid Tumors ""; ""7. Cancer Cell Dormancy and Resistant Cancer Stem Cells ""; ""MODULATION OF MDR PHENOTYPE "" 327 $a""I. Circumvention of Drug Resistance Induced by P-Gp Pump Protein "" 410 0$aCancer etiology, diagnosis, and treatments. 606 $aBreast$xCancer 606 $aBreast$xDiseases 615 0$aBreast$xCancer. 615 0$aBreast$xDiseases. 676 $a616.99/449 676 $a616.99/449 701 $aDeFrina$b Regina H$01673512 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910825074903321 996 $aAggressive breast cancer$94037646 997 $aUNINA